GLP-1 Analogs for Type 2 Diabetes

Overview

GLP-1 analogs are injectable drugs for type 2 diabetes that mimic GLP-1 to lower blood glucose without usually causing hypoglycemia.

GLP-1 Analogs: Basics

• GLP-1 stands for glucagon-like peptide-1, an incretin hormone that helps regulate blood glucose.
• GLP-1 analogs are man‑made molecules that imitate natural GLP-1’s actions.
• They bind GLP-1 receptors and trigger similar physiological effects as the endogenous hormone.

Drug Names and Clinical Use

• Main examples: exenatide and liraglutide.
• Primarily used for type 2 diabetes mellitus, not type 1.
• Main therapeutic goal: lower elevated blood glucose levels.

GLP-1 Analogs: Summary Table

Mechanisms of Action

• GLP-1 analogs mimic endogenous GLP-1 activity at GLP-1 receptors.
• Overall effect: reduce blood glucose by enhancing insulin action, limiting glucagon, slowing nutrient absorption, and reducing food intake.

Glucose-Dependent Insulin Release

• Stimulate insulin release from pancreatic beta cells in a glucose‑dependent manner.
• When blood glucose is elevated, they trigger an indirect hormonal cascade → increased insulin secretion.
• When glucose is low, this cascade shuts off, limiting further insulin release.
• Result: glucose moves from blood into cells, lowering blood glucose while preserving feedback safety.

Decreased Glucagon Release

• Decrease secretion of glucagon from pancreatic alpha cells.
• Glucagon normally raises blood glucose by:
  • Promoting glycogen breakdown (glycogenolysis) in the liver.
  • Promoting new glucose production (gluconeogenesis).
• Reduced glucagon → less hepatic glucose output → lower blood glucose.

Decreased Gastric Emptying

• Slow the rate at which stomach contents move into the small intestine (decreased gastric emptying).
• Slower gastric emptying → smaller amount of food enters intestines at one time.
• Leads to reduced rate of glucose absorption from the gut into the bloodstream.
• Blunts post‑meal (postprandial) blood glucose spikes.

Increased Satiety

• Increase satiety (sense of fullness after eating).
• Increased fullness → patients eat less overall food.
• Less food intake → less glucose absorbed → additional lowering of blood sugar.
• Often considered both a mechanism and a “beneficial side effect” for many patients.

Side Effects and Safety

• Side effects are important for choosing therapy and counseling patients beginning GLP‑1 analog treatment.

Common Side Effect: Nausea and Vomiting

• Nausea and vomiting are very common, affecting up to about half of patients.
• Likely related to altered gut motility and enhanced GLP-1 signaling.
• Patients started on exenatide or liraglutide often report these gastrointestinal complaints.

Serious but Rare Side Effect: Pancreatitis

• Can cause pancreatitis (inflammation of the pancreas), which is rare but potentially life‑threatening.
• Pancreatitis may present with severe abdominal pain shortly after starting the drug.
• Clinicians should evaluate for pancreatitis if such pain occurs in a patient on GLP‑1 analogs.

Weight Loss

• GLP-1 analogs are associated with weight loss.
• Weight loss likely results from:
  • Increased satiety (eating less).
  • Nausea/vomiting in some patients.
• Weight loss can be desirable, but is still categorized as a notable effect to remember.

Low Risk of Hypoglycemia

• GLP-1 analogs generally do not cause hypoglycemia when used alone.
• Reason: insulin release is glucose‑dependent with preserved feedback control.
  • When glucose is low, insulin secretion triggered by GLP‑1 analogs stops.
• Contrast with:
  • Direct insulin injections: can cause hypoglycemia because insulin is given regardless of blood glucose level.
  • Sulfonylureas and other direct insulin secretagogues: stimulate insulin release without adequate feedback, risking hypoglycemia.

Key Terms & Definitions

• GLP-1 (glucagon-like peptide-1): Hormone that enhances insulin secretion in response to oral glucose.
• GLP-1 analogs: Synthetic drugs that mimic GLP-1’s actions at its receptor.
• Type 2 diabetes mellitus: Metabolic disease with high blood glucose due to insulin resistance and/or impaired insulin secretion.
• Insulin: Pancreatic hormone that lowers blood glucose by promoting cellular glucose uptake.
• Glucagon: Pancreatic hormone that raises blood glucose by stimulating hepatic glucose production.
• Gastric emptying: Movement of stomach contents into the small intestine.
• Satiety: Feeling of fullness that reduces further food intake.
• Pancreatitis: Inflammation of the pancreas, often presenting with severe abdominal pain.
• Hypoglycemia: Abnormally low blood glucose level that can be dangerous.

Action Items / Next Steps

• Memorize the main GLP-1 analog names: exenatide and liraglutide.
• Be able to list and explain four main mechanisms: ↑ glucose‑dependent insulin, ↓ glucagon, ↓ gastric emptying, ↑ satiety.
• Learn key side effects: common (nausea/vomiting, weight loss) versus serious (pancreatitis).
• Understand why GLP-1 analogs rarely cause hypoglycemia compared with insulin and sulfonylureas.